Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.58 |
| ▸ | GPR183 | P32249 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | TACR3 | P29371 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16598603 | 1.00 | MEN1 (0.60) | MEN1KMT2ALMNAKCNA5GPR183 | |
| SCHEMBL19412459 | 0.80 | MEN1 (0.57) | MEN1KMT2ALMNAGPR183POLB | |
| SCHEMBL5026257 | 0.78 | KCNA5 (0.59) | MEN1KMT2ALMNAKCNA5KDM4E | |
| SCHEMBL16598994 | 0.77 | GPR183 (0.74) | MEN1KMT2ALMNAGPR183KDM4E | |
| SCHEMBL16598991 | 0.77 | GPR183 (0.74) | MEN1KMT2ALMNAGPR183KDM4E | |
| SCHEMBL5480294 | 0.76 | HPGD (0.61) | MEN1KMT2ALMNAKCNA5KDM4E | |
| SCHEMBL11026534 | 0.76 | POLB (0.67) | MEN1KMT2ALMNAGPR183KDM4E | |
| SCHEMBL11026533 | 0.76 | POLB (0.67) | MEN1KMT2ALMNAGPR183KDM4E | |
| SCHEMBL17938699 | 0.75 | GPR183 (0.93) | MEN1KMT2AGPR183POLBTACR3 | |
| SCHEMBL17938698 | 0.75 | GPR183 (0.93) | MEN1KMT2AGPR183POLBTACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9776979-B2 | EBI2 modulators | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2017-10-03 | — | — | US | disclosed |
| US-20160214951-A1 | EBI2 MODULATORS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2016-07-28 | — | — | US | disclosed |
| WO-2015048570-A2 | EBI2 MODULATORS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214951-A1 | EBI2 MODULATORS | BIRC2, HAVCR2, MAVS | MEN1 2201/4885KMT2A 1057/4885LMNA 2951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.